Overview

AD109 Dose Finding in Mild to Moderate OSA

Status:
Completed

Trial end date:
2021-05-31

Target enrollment:

Participant gender:

Summary

This is a randomized, 3-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of 2 doses of AD109 vs placebo in patients with mild obstructive sleep apnea.

Phase:

Phase 2

Details

Lead Sponsor:

Apnimed